drugset / Trial / NCT02973100

A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

NCT02973100

Phase 2 Completed 318 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.

Timeline

Start
2016-12
Primary completion
2017-07-15
Completion
2017-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Dulaglutide Peptide 1.5 mg Subcutaneous
Subject Dulaglutide Peptide 3 mg Subcutaneous
Subject Dulaglutide Peptide 4.5 mg Subcutaneous